• 1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Methylpyridines

Comprehensive Overview of (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine (CAS No. 1213455-10-7)

(1S)-1-(2-methylpyridin-3-yl)ethan-1-amine, with the CAS number 1213455-10-7, is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various biological and therapeutic applications. This comprehensive overview aims to provide an in-depth understanding of the chemical properties, synthesis methods, biological activities, and recent research advancements related to this compound.

Chemical Structure and Properties

(1S)-1-(2-methylpyridin-3-yl)ethan-1-amine is a chiral amine with a molecular formula of C₉H₁₂N₂. The compound features a 2-methylpyridine ring attached to an ethylamine moiety, with the chiral center located at the carbon atom adjacent to the nitrogen atom. This specific configuration imparts unique stereochemical properties to the molecule, which are crucial for its biological activities and interactions with target proteins.

The compound is typically synthesized through asymmetric catalytic methods, ensuring high enantiomeric purity. Its physical properties include a melting point of approximately 65°C and a boiling point around 200°C. It is moderately soluble in water and highly soluble in organic solvents such as ethanol and methanol. These solubility characteristics make it suitable for various experimental conditions and formulations.

Synthesis Methods

The synthesis of (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine has been extensively studied, with several methods reported in the literature. One of the most common approaches involves the asymmetric hydrogenation of a prochiral precursor. For instance, a prochiral ketone can be reduced using a chiral catalyst, such as a ruthenium-based catalyst, to produce the desired enantiomer with high selectivity. Another method involves the use of chiral auxiliaries or resolving agents to achieve enantiomeric enrichment.

A recent study published in the Journal of Organic Chemistry (JOC) described a novel one-pot synthesis method that combines palladium-catalyzed cross-coupling with asymmetric hydrogenation. This method not only simplifies the synthetic route but also improves yield and enantiomeric purity. The researchers reported that this approach could be scaled up efficiently for industrial production, making it a promising method for large-scale synthesis.

Biological Activities and Therapeutic Potential

(1S)-1-(2-methylpyridin-3-yl)ethan-1-amine has been investigated for its potential therapeutic applications due to its ability to interact with various biological targets. One of the key areas of interest is its activity as a modulator of neurotransmitter systems, particularly in the central nervous system (CNS). Studies have shown that this compound can act as an agonist or antagonist at specific receptors, influencing neurotransmitter release and receptor signaling.

A notable study published in the Journal of Medicinal Chemistry (JMC) demonstrated that (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine exhibits potent activity as a selective serotonin reuptake inhibitor (SSRI). This property makes it a potential candidate for treating mood disorders such as depression and anxiety. The researchers conducted preclinical studies using animal models and found that the compound significantly reduced depressive-like behaviors without causing significant side effects.

In addition to its CNS activity, (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine has also shown promise in other therapeutic areas. For example, it has been evaluated for its anti-inflammatory properties and potential use in treating inflammatory diseases such as arthritis. A study published in the European Journal of Pharmacology (EJP) reported that the compound inhibited pro-inflammatory cytokine production in vitro and reduced inflammation in animal models of arthritis.

Clinical Trials and Future Directions

The promising preclinical results have led to increased interest in advancing (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine into clinical trials. Several pharmaceutical companies are currently conducting Phase I trials to evaluate the safety and pharmacokinetics of this compound in humans. Preliminary data from these trials have been encouraging, with no significant adverse effects reported at therapeutic doses.

The future directions for research on (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine include further optimization of its chemical structure to enhance potency and selectivity. Additionally, combination therapy approaches are being explored to leverage its synergistic effects with other drugs. For instance, combining this compound with existing SSRIs or anti-inflammatory agents may provide more effective treatment options for patients.

In conclusion, (1S)-1-(2-methylpyridin-3-yl)ethan-1-amine (CAS No. 1213455-10-7) is a promising chiral compound with diverse biological activities and therapeutic potential. Its unique chemical structure and stereochemistry make it an attractive candidate for further development in medicinal chemistry and pharmaceutical research. As ongoing studies continue to uncover new insights into its mechanisms of action and clinical applications, this compound holds significant promise for improving patient outcomes in various medical conditions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)